Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SGML +10.3%, USAR +1%
Other news:
- ROMA +33% (authorizes $100 mln share repurchase program)
- UTHR +14.8% (announces that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis met its primary efficacy endpoint)
- IQ +11.7% (proposes Hong Kong listing, authorizes $100 mln buyback)
- CNTB +11.3% (announces $20.2 million private placement financing; results from a Phase 3 52-week study in patients with moderate-to-severe atopic dermatitis conducted by the Company's partner in China, Simcere Pharmaceutical Co., Ltd. , which were presented during the Late-Breaking Research session of the 2026 American Academy of Dermatology (AAD) Annual Meeting)
- SGHT +8.2% (secures order on post-trial motions that preserves the Jury's Verdict and awards monetary damages to Sight Sciences against Alcon (ALC) and its Hydrus Microstent)
- CORT +7.7% (presents data from MOMENTUM trial at American College of Cardiology Annual Scientific Session)
- ROIV +5.7% (reports New England Journal of Medicine publishes Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis)
- NKTR +4.1% (reports data from Phase 2b REZOLVE-AD and REZOLVE-AA studies of Rezpegaldesleukin presented at 2026 American Academy of Dermatology Annual Meeting)
- RIO +3.8% (resumes Pilbara iron ore operations after cyclone disruption)
- ALMS +3.3% (Envudeucitinib delivers early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis)
- MLTX +2.5% (reports Week 40 results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting)
- PANW +2.5% (CEO disclosed the purchase of 68,085 shares at $146.46 - $147.48 worth ~ $10 mln)
- KYMR +2.2% (presents KT-621 BroADen data in late-breaking research session at the American Academy of Dermatology (AAD) Annual Meeting)
- TAK +2% (Zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care)
- IDYA +2% (announces first-patient-in for Phase 1 combination study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 upregulated solid tumor indications, including SCLC, NETs, NECs, and melanoma)
- ARBK +2% (entered into a subscription facility agreement with controlling shareholder Growler Mining Tuscaloosa providing access to a subscription facility of up to $5mln; has received $2.5 mln in initial proceeds)
- NPK +1.9% (announces U.S. Army defense segment award)
- BUR +1.9% (addresses YPF appeal outcome, expects write-down but no cash impact)
- BTDR +1.8% (partners with DCI to advance Norway AI data center project)
- ARQT +1.7% (presents new Phase 2 results in infants with atopic dermatitis in late-breaking session at the 2026 American Academy of Dermatology Annual Meeting)
- ZYME +1.7% (gains FDA Fast Track for ZW191 in ovarian cancer)
- WBI +1.3% (files for 83,250,000 Class A share offering by selling shareholders)
- BSX +1.2% (reports HI-PEITHO trial demonstrates EKOS Endovascular System is superior to standard of care for treatment of acute pulmonary embolism; CHAMPION-AF study of the WATCHMAN FLX Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and efficacy endpoints)
- ARWR +1.2% (presents new long-term efficacy and safety data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo)